WO2019227255A1 - miRNA-128过表达载体的构建及其应用 - Google Patents

miRNA-128过表达载体的构建及其应用 Download PDF

Info

Publication number
WO2019227255A1
WO2019227255A1 PCT/CN2018/088530 CN2018088530W WO2019227255A1 WO 2019227255 A1 WO2019227255 A1 WO 2019227255A1 CN 2018088530 W CN2018088530 W CN 2018088530W WO 2019227255 A1 WO2019227255 A1 WO 2019227255A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
mirna
overexpression
expression vector
construction
Prior art date
Application number
PCT/CN2018/088530
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2018/088530 priority Critical patent/WO2019227255A1/zh
Publication of WO2019227255A1 publication Critical patent/WO2019227255A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Definitions

  • the invention belongs to the field of genetic engineering, and particularly relates to the construction and application of a miRNA-128 overexpression vector.
  • MicroRNA is a type of small single-stranded short RNA with a length of about 22 to 25 nucleotides. Although it does not encode a protein, it can bind to homologous mRNA in an incomplete base-pairing manner and inhibit it. The expression of mRNA may induce its degradation, thereby negatively regulating mRNA and affecting the production of related proteins.
  • miRNAs are regulated by miRNAs, and they are almost involved in a series of physiological and biochemical processes such as cell growth, differentiation, apoptosis, glucose metabolism, fat metabolism, insulin secretion, brain formation, cardiac development, and stem cell differentiation. The occurrence of diseases, including tumors, is closely related.
  • Prostate cancer is a common malignant tumor in older men.
  • prostate cancer is the second most common cancer among men.
  • the incidence of prostate cancer in Asia is much lower than in Europe and the United States, but it has also shown an upward trend in recent years, and the growth is more rapid than in developed countries such as Europe and the United States.
  • the incidence of prostate cancer in our country is also increasing year by year.
  • prostate cancer has become the most frequently occurring tumor in the male urogenital system in China since 2008, with an incidence rate of 9.92 per 100,000 in 2009, ranking sixth in the incidence of male malignant tumors. With a mortality rate of 4.19 / 100,000, it ranks 9th among all male malignancies.
  • the present invention studies the role of miR-128 in tumors by constructing miR-128 overexpression recombinant vectors and over-expressing them in LNCap cells.
  • the experimental results showed that the recombinant vector was successfully and efficiently expressed at the cell level, and the expression level of miR-128 was greatly increased.
  • the object of the present invention is to provide a miR-128 overexpression recombinant expression vector, which contains the sequence shown in SEQ ID No.1.
  • the vector is pcDNA3.1.
  • Another object of the present invention is to provide a method for constructing the miR-128 overexpression recombinant expression vector, which method comprises: a. Designing primers and PCR amplifying the miR-128 gene; b. Combining the amplified gene and expression vector enzyme Cut, ligate the gene of interest and the expression vector; c. Transform the ligated product into E. coli and culture; d. Extract the recombinant plasmid after identification.
  • upstream primer 5'-TGAGCTGTTGGATTCGGGGC-3 '
  • downstream primer 5'-GCAGCTGAAAAAGAGACCG-3'.
  • the miR-128 overexpression recombinant vector provided by the present invention can greatly increase the expression level of miR-128 in tumor cells, and provides a new technical means for studying the role of miR-128 in tumorigenesis and development.
  • Figure 1 shows miR-128 expression levels of LNCap cells in the control and experimental groups.
  • the newly synthesized primers were dissolved in TE buffer and adjusted to a final concentration of 10 ⁇ mol / L.
  • primers were added, and Premix PrimeSTAR HS was used for amplification.
  • the amplification conditions were as follows: 98 ° C 5 min, 1 Cycles: 98 ° C 5 s, 56 ° C 5 s, 72 ° C 10 s, 30 cycles.
  • the PCR product was electrophoresed on a 1% agarose gel, and then the gel was recovered to purify the purified PCR product.
  • a 100 ⁇ g / ml ampicillin-containing LB medium was used to culture a large number of correctly sequenced Escherichia coli at 37 ° C.
  • the pcDNA-miR128 recombinant plasmid was extracted without endotoxin.
  • LNCap cells were seeded into six-well plates at a seeding density of 50%.
  • Transfection Take 1 ⁇ g pcDNA-miR128 recombinant plasmid and 3 ⁇ l PEI (1 ⁇ g / ⁇ l) in 100 ⁇ l Opti-MEM medium, and vortex to mix. The medium in the six-well plate was changed to serum-free medium, 1.4 ml per well, and 600 ⁇ l of the transfection mixture was added, and replaced with DMEM medium preheated with 10% fetal bovine serum at 37 ° C. for 5 h. Incubate at 37 ° C for 5% CO2, 90% humidity for 48 h, and collect cells.
  • Example 2 The total RNA of the cells collected in Example 2 was quantified by the probe method Hairpin-it miRNAs quantification and U6 calibration qRT-PCR kit (GenePharma) for fluorescent quantitative PCR. For specific methods, refer to the kit instructions. The results are shown in Figure 1.
  • LNCap cells (experimental group) transfected with pcDNA-miR128 recombinant plasmid were detected by fluorescent quantitative PCR, and the expression level of miR-128 was 129.6 times higher than that of normal LNCap cells (control group), indicating that pcDNA-miR128 recombinant plasmid Can efficiently express miR-128.
  • the miR-128 overexpression recombinant vector provided by the present invention can greatly increase the expression level of miR-128 in tumor cells, and provides new technical means for studying the role of miR-128 in tumorigenesis and development.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了一种miRNA-128过表达重组载体的构建及应用。通过构建miR-128过表达重组载体并在LNCap细胞中过表达，研究miR-128在肿瘤中的作用。

Description

miRNA-128过表达载体的构建及其应用 技术领域
本发明属于基因工程领域，尤其涉及一种miRNA-128过表达载体的构建及其应用。
 背景技术
MicroRNA（miRNA）是一类长度约为22～25个核苷酸的单链短序列小RNA，尽管其不编码蛋白质，但却能以非完全性碱基配对的方式结合于同源mRNA，抑制mRNA的表达或是诱导其降解，从而对mRNA进行负性调控，影响相关蛋白的生成。人类有三分之一的基因受miRNA调控，几乎参与了细胞生长、分化、凋亡、糖代谢、脂肪代谢、胰岛素分泌、大脑形成、心脏发生、干细胞分化等一系列生理生化进程，并与许多疾病（包括肿瘤）的发生密切相关。
 技术问题
前列腺癌是老年男性常见的恶性肿瘤。在世界范围内，前列腺癌发病率在男性所有恶性肿瘤中位居第二。亚洲前列腺癌的发病率远远低于欧美国家，但近年来也呈现上升趋势，且增长比欧美等发达国家更为迅速。同样，我国前列腺癌的发病率也在逐年上升。根据国家癌症中心的最新数据，前列腺癌自2008年起成为我国男性泌尿生殖系统中发病率最高的肿瘤，2009年的发病率达到9.92/10万，在男性恶性肿瘤发病率排名中排第6位，死亡率达到4.19/10万，在所有男性恶性肿瘤中排第9位。有研究表明，miRNA-128在前列腺癌患者和正常人体内的表达水平有较大差别，但miRNA-128在前列腺癌的发病过程中所起作用及其机制尚不清楚，相关的研究报道较少。
 技术解决方案
本发明通过构建miR-128过表达重组载体并在LNCap细胞中过表达，研究miR-128在肿瘤中的作用。实验结果显示，该重组载体在细胞水平成功高效表达，miR-128表达水平大幅提升。
本发明的目的是提供miR-128过表达重组表达载体，其含有如SEQ ID No.1所示的序列。
所述载体为pcDNA3.1。
本发明的另一个目的是提供构建所述miR-128过表达重组表达载体的方法，该方法包括：a. 设计引物，PCR扩增miR-128基因；b. 将扩增的基因和表达载体酶切，连接目的基因和表达载体；c. 将连接产物转化大肠杆菌，培养；d. 鉴定后提取重组质粒。
所述引物序列：上游引物：5’-TGAGCTGTTGGATTCGGGGC-3’；下游引物：5’-GCAGCTGAAAAAGAGACCG-3’。
 有益效果
本发明提供的miR-128过表达重组载体可大幅提升miR-128在肿瘤细胞中的表达水平，为研究miR-128在肿瘤发生发展中的作用提供了新的技术手段。
 附图说明
图1为对照组和实验组LNCap细胞的miR-128表达水平。
 本发明的实施方式
下面结合附图与具体实施例对本发明做进一步的说明。
实施例一 miR-128 过表达载体构建
1、序列获得和引物设计
从Genbank中找到人miR-128基因序列（登录号：AC016742.10），利用Primer 5软件分别选取各个CDS两端的部分序列进行分析，确定上下游引物序列，并委托上海英潍捷基公司合成引物。所述引物序列：上游引物：5’-TGAGCTGTTGGATTCGGGGC-3’；下游引物：5’-GCAGCTGAAAAAGAGACCG-3’。
2、目的基因序列的获得
将新合成的引物加入TE buffer溶解，调整引物的最终浓度为10 μmol/L，以LNCap细胞基因组DNA为模板，加入引物，Premix PrimeSTAR HS进行扩增，扩增条件如下：98℃ 5 min，1个循环；98℃ 5 s，56℃ 5 s，72℃ 10 s，30个循环。PCR产物通过1%琼脂糖凝胶电泳，然后切胶回收纯化PCR产物。
Bam HI和Xho I分别双酶切pcDNA3.1质粒和PCR产物，回收后按pcDNA3.1质粒：PCR产物为1:5混合后，T4 DNA连接酶16℃连接过夜。转化大肠杆菌Top 10，氨苄青霉素筛选培养并挑单克隆菌株，测序鉴定，获得pcDNA-miR128质粒。
实施例二 LNCap 细胞转染
用含100 μg/ml氨苄青霉素的LB培养基，37℃大量培养测序正确的大肠杆菌，无内毒素提取pcDNA-miR128重组质粒。
转染前一天将LNCap细胞接种至六孔板，接种密度50%。转染：取1 μg pcDNA-miR128重组质粒和3 μl PEI（1 μg/μl）溶于100 μl Opti-MEM培养基，涡旋混匀。将六孔板内培养基换成无血清培养基，每孔1.4 ml，并加入600 μl转染混合液，5 h换成37℃预热有10% 胎牛血清的DMEM培养基。置37℃ 5% CO2，90% 湿度培养48 h，收集细胞。
实施例三   miR-128 表达水平的鉴定
提取实施例二中收集细胞的总RNA，探针法Hairpin-it miRNAs定量和U6校准qRT-PCR试剂盒(GenePharma)进行荧光定量PCR，具体方法参照试剂盒说明书，结果见图1。
如图1所示，荧光定量PCR检测转染了pcDNA-miR128重组质粒的LNCap细胞（实验组），其miR-128表达水平较正常LNCap细胞（对照组）高129.6倍，说明pcDNA-miR128重组质粒可高效表达miR-128。
 工业实用性
本发明提供的miR-128过表达重组载体可大幅提升miR-128在肿瘤细胞中的表达水平，为研究miR-128在肿瘤发生发展中的作用提供了新的技术手段。

Claims (3)

  1. 一种miR-128过表达重组表达载体，其含有如SEQ ID No.1所示的序列。
  2. 构建权利要求1所述的miR-128过表达重组表达载体的方法，该方法包括：a. 设计引物，PCR扩增miR-128基因；b. 将扩增的基因和表达载体酶切，连接目的基因和表达载体；c. 将连接产物转化大肠杆菌，培养；d. 鉴定后提取重组质粒。
  3. 根据权利要求2所述的方法，其中所述引物为：
    上游引物：5’-TGAGCTGTTGGATTCGGGGC-3’
    下游引物：5’-GCAGCTGAAAAAGAGACCG-3’
PCT/CN2018/088530 2018-05-26 2018-05-26 miRNA-128过表达载体的构建及其应用 WO2019227255A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/088530 WO2019227255A1 (zh) 2018-05-26 2018-05-26 miRNA-128过表达载体的构建及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/088530 WO2019227255A1 (zh) 2018-05-26 2018-05-26 miRNA-128过表达载体的构建及其应用

Publications (1)

Publication Number Publication Date
WO2019227255A1 true WO2019227255A1 (zh) 2019-12-05

Family

ID=68697353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/088530 WO2019227255A1 (zh) 2018-05-26 2018-05-26 miRNA-128过表达载体的构建及其应用

Country Status (1)

Country Link
WO (1) WO2019227255A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667347A (zh) * 2012-09-08 2014-03-26 刘佳 一种高效表达抗癌基因的受特定miRNA调控的在胶质瘤细胞中特异增殖的腺病毒及其用途
CA2929098A1 (en) * 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
WO2016040347A2 (en) * 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667347A (zh) * 2012-09-08 2014-03-26 刘佳 一种高效表达抗癌基因的受特定miRNA调控的在胶质瘤细胞中特异增殖的腺病毒及其用途
CA2929098A1 (en) * 2013-10-28 2015-05-07 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
WO2016040347A2 (en) * 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank 10 April 2018 (2018-04-10), XIAO, M. ET AL.: "Homo Sapiens microRNA 128-1(MIR128-1), microRNA", XP055657687, Database accession no. NR_029672.1 *
NIU, REN: "The Study of miRNA-128 Expression and Biological Function in Lung Cancer", CHINESE MASTER'S THESES FULL-TEXT DATABASE, MEDICAL AND HEALTH SCIENCE S, 15 September 2014 (2014-09-15) *

Similar Documents

Publication Publication Date Title
JP5735927B2 (ja) タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作
CN108753779B (zh) 牛lncRNA-133a及在牛骨骼肌卫星细胞增殖分化调控中的应用和验证方法
CN111154763B (zh) 长链非编码RNA lncMGPF在调控猪肌肉发育功能中的应用
CN109837301B (zh) 人源化幽门螺旋杆菌cagA真核表达载体构建方法
CN112899238B (zh) 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用
CN105861551B (zh) 联合表达microRNAs抑制乳腺癌细胞增殖的载体及其构建方法和应用
CN109486816B (zh) 一种用于肿瘤治疗的多聚核苷酸及其应用
CN114517198B (zh) 一种半滑舌鳎miRNA及其在调控tgfb2基因表达中的应用
WO2019227255A1 (zh) miRNA-128过表达载体的构建及其应用
Li et al. MiR-218 affects the invasion and metastasis of cervical cancer cells by inhibiting the expression of SFMBT1 and DCUNIDI
CN106831975B (zh) 热休克转录因子1在调控15kDa硒蛋白表达中的应用
WO2019227256A1 (zh) miRNA-145过表达载体的构建及其应用
CN110893240B (zh) Nme2基因在抑制禽呼肠病毒复制中的应用
WO2019227257A1 (zh) miRNA-210过表达载体的构建及其应用
WO2019227254A1 (zh) miRNA-25过表达载体的构建及其应用
WO2019227253A1 (zh) miRNA-21过表达载体的构建及其应用
CN108588221B (zh) Stil基因的用途及其相关药物
CN116904469B (zh) 一种p300蛋白表达的抑制剂和制备方法及其用途
CN113227375A (zh) 合成的微小rna模拟物
CN114107495B (zh) Duxap8在子宫内膜癌诊断、治疗和预防中的应用
CN115896112B (zh) 靶向敲除人TMEM121基因的sgRNA，构建该基因缺失细胞株的方法及应用
CN110042121B (zh) 一种促进白血病细胞分化的方法及其应用
CN109097399A (zh) 长链非编码rna h19的表达载体、表达h19的细胞株及其应用
CN110527682B (zh) 一种长链非编码rna及其应用
CN117187249B (zh) 一种牦牛Lnc-MEG8基因及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18920850

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18920850

Country of ref document: EP

Kind code of ref document: A1